Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications

The evolution of pediatric solid tumors is poorly understood. There is conflicting evidence of intra-tumor genetic homogeneity vs. heterogeneity (ITGH) in a small number of studies in pediatric solid tumors. A number of copy number aberrations (CNA) are proposed as prognostic biomarkers to stratify...

Full description

Saved in:

Bibliographic Details
Published in:	EBioMedicine Vol. 9; no. C; pp. 120 - 129
Main Authors:	Cresswell, George D., Apps, John R., Chagtai, Tasnim, Mifsud, Borbala, Bentley, Christopher C., Maschietto, Mariana, Popov, Sergey D., Weeks, Mark E., Olsen, Øystein E., Sebire, Neil J., Pritchard-Jones, Kathy, Luscombe, Nicholas M., Williams, Richard D., Mifsud, William
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-07-2016 Elsevier
Subjects:	Alleles Biomarkers, Tumor - genetics Child, Preschool Chromosomes, Human, Pair 11 Clonal Evolution Copy number aberrations Female Gene Dosage Genome Humans Infant Intra-tumor genetic heterogeneity Kidney Neoplasms - diagnostic imaging Kidney Neoplasms - genetics Kidney Neoplasms - pathology Loss of Heterozygosity - physiology Magnetic Resonance Imaging Male Molecular biomarkers Oligonucleotide Array Sequence Analysis Pediatric solid tumors Research Paper Tumor evolution Tumor multisampling Wilms tumor Wilms Tumor - diagnostic imaging Wilms Tumor - genetics Wilms Tumor - pathology Intra-tumor genetic heterogeneity Copy number aberrations Pediatric solid tumors Wilms tumor Tumor evolution Tumor multisampling Molecular biomarkers
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The evolution of pediatric solid tumors is poorly understood. There is conflicting evidence of intra-tumor genetic homogeneity vs. heterogeneity (ITGH) in a small number of studies in pediatric solid tumors. A number of copy number aberrations (CNA) are proposed as prognostic biomarkers to stratify patients, for example 1q+ in Wilms tumor (WT); current clinical trials use only one sample per tumor to profile this genetic biomarker. We multisampled 20 WT cases and assessed genome-wide allele-specific CNA and loss of heterozygosity, and inferred tumor evolution, using Illumina CytoSNP12v2.1 arrays, a custom analysis pipeline, and the MEDICC algorithm. We found remarkable diversity of ITGH and evolutionary trajectories in WT. 1q+ is heterogeneous in the majority of tumors with this change, with variable evolutionary timing. We estimate that at least three samples per tumor are needed to detect >95% of cases with 1q+. In contrast, somatic 11p15 LOH is uniformly an early event in WT development. We find evidence of two separate tumor origins in unilateral disease with divergent histology, and in bilateral WT. We also show subclonal changes related to differential response to chemotherapy. Rational trial design to include biomarkers in risk stratification requires tumor multisampling and reliable delineation of ITGH and tumor evolution. •There is remarkable diversity of intratumor genetic heterogeneity and evolutionary trajectories.•Gain of 1q is frequently heterogeneous and shows variable evolutionary timing.•11p15 CNNLOH is consistently an early event in Wilms tumorigenesis.•Rational biomarker-based treatment stratification in Wilms tumors requires multisampling.We have shown that Wilms tumor (WT), the commonest pediatric kidney cancer, shows a range of evolutionary trajectories. We also found that gain of the long arm of chromosome 1 (1q+) may occur both early or late in the evolution of WT. 1q+ is associated with a poorer outcome and is proposed for use in choosing patients for more intensive treatment, but we show that in order to detect it reliably, future trials require testing for this biomarker in multiple samples per tumor.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work.
ISSN:	2352-3964 2352-3964
DOI:	10.1016/j.ebiom.2016.05.029